Historically, digital rectal examination (DRE) had been the only method available to evaluate the prostate gland for malignant tumor. Recently, serum prostate specific antigen (PSA), transretal ultrasonlography (TRUS) and magnetic resonance
imaging
(MRI) using endo-rectal coil have been added to the methods used to detect prostate cancer. But the roles of these tests in detecting cancer are currently undefined. Because of its low specificity, some reports have suggested the routine use of
TRUS be
discouraged. The present study was undertaken to evaluate the value of TRUS in the detection of prostate cancer.
In a retrospective study, 123 BPH patients were examined by TRUS and PSA measurement. All patients were planned for prostatectomy and they had no evidence for prostate cancer at DRE. Of 123 patines with pathologically proven diagnosis, 10 patiens
had
prostate cancer and 113 patines had BPH. Among the patines with prostate cancer, 6 patiens has elevated PSA level (>10ng/mL), while a patient has normal PSA levels were between 4 and 10ng/mL, only 3 patiens had prostate cancer. Among 10 patiens
with
prostate cancer, one patient had positive finding in TRUS, while 9 patients had negative finding. Among 11 patines with BPH, 17 patients had positive findings in TRUS and 96 patines had negative findings. Over all TRUS sensitivity and specificity
for
prostate cancer detection was 10% and 84.9% respectively.
@ES From our data we conclude;
@EN 1. The use of TRUS in BPH patients with negative DRE and PSA less than 10ng/mL seems to be questionable. 2. For the patients with negative DRE and PSA higher than 10ng/mL, sono-guided biopsy should be done regardless of the result of TRUS.
|